The Scottish-born CEO of Pfizer Inc., Ian Read, has revamped the US-based drug maker and turned it into a Wall Street darling over the past five years via a series of moderate-sized acquisitions, spin-offs and strategic cost-cutting moves – but his next acquisition, if allowed by US authorities, seems likely to cement his reputation as a major deal-maker.
Under Read's leadership Pfizer is now courting Dublin, Ireland-based Allergan Inc. in a fresh tax inversion attempt despite changes to...